Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

To join this study, you must be a woman aged 18 or older with newly diagnosed advanced ovarian, fallopian tube, or peritoneal cancer. This includes certain stages of the cancer (FIGO stage III/IV) that haven't spread too widely.

You must have already had surgery to remove as much of the cancer as possible, or be scheduled to have surgery after starting chemotherapy. Your cancer cells will also be tested to check for specific genetic changes before you can join the main part of the study. You'll need to be in reasonably good general health, meaning you can do light daily activities and your blood tests show your body is working well enough to handle the treatments.

There are also some medical conditions or past treatments that might mean this study isn't right for you, especially if you can't safely take the medicines being tested. Your doctor will carefully review all your medical information to see if you meet all the requirements.

If you decide to join, the study starts with one cycle of standard chemotherapy (carboplatin and paclitaxel). During this time, a small piece of your cancer tissue will be sent for special tests to look at your `BRCA` gene. Based on these results, you'll be randomly assigned to one of two treatment groups – like flipping a coin, so it's fair. You will then receive five more cycles of chemotherapy. One group will get these with bevacizumab, and the other won't.

After chemotherapy, your treatment continues for up to three years. One group will take niraparib daily. The other group will take niraparib daily AND receive bevacizumab injections every three weeks for up to a year. You'll have regular hospital visits for treatments, blood tests, and check-ups to see how you're doing and how the treatment is working. The total duration of active treatment will vary depending on the group you're in, but follow-up could continue for several years.